Myalgia Musculoskeletal Diseases Myalgia
Conditions
Interventions
Study group: Loxoprofen Sodium Cataplasm ointment once daily, one patch each time (100 mg) + placebo tablet 3 times daily, 1 tablet each time (60 mg)
Control group: Placebo Cataplasm
Sponsors
Lead Chemical Co. Ltd (Japan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age: > 18 years, < 80 years, 18 and 80 years included 2. Either sex 3. Any of the following with moderate intensity: resting pain, pressing pain, exercising pain 4. The patients were not treated by drugs for one week before giving the investigational product, and no change in physiotherapy for 2 weeks during the first treatment. 5. Patients agree to participate in the trial and sign informed content form after completely understanding the contents of the clinical trial
Exclusion criteria
Exclusion criteria: 1. Patient's pain caused by external injury and diagnosed as acute 2. Patient's pain diagnosed as neurosis 3. Patients with lesions, poor skin conditions on pasting site, or with cutaneous anaphylaxis 4. Patients who need steroid drugs or other non-steroid analgesics which may interfere the therapeutic method in this clinical trial. 5. Patient with peptic ulcer. 6. Patients with bronchial asthma. 7. Patients with serious cardiac diseases, hepatic diseases (ALT, AST are equal or bigger than 2.5 times of upper limit), renal diseases (creatinine is equal or bigger than 1.5 times of upper limit), hematologic disease, diabetes, mental diseases, and other serious complications. 8. Pregnant women, lactating mothers or patients who have the possibility of pregnancy, and want to be pregnant during the trial. 9. Patient allergic to this drug. 10. Patients participating any clinical trials on investigational drug or marketed drug within 3 months before enrollment or during clinical trial 11. Other patients judged to be inappropriate for this clinical trial by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physical test, including the following four symptoms (rest pain, pressing pain, exercising pain, limited movement); each symptom has four grades: no effect, slightly, median, heavily. Timepoint: measured at baseline, 1 week after treatment, 2 weeks after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Effective rates against different symptoms | — |
Countries
China
Outcome results
None listed